Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16628
Sealed predictions
- EFCAB13 in dopamine neurons, braak-0.17 (p 0.663) → +0.75 (p 0.019)receipt 16637
Swarm cases
receipt 16637: EFCAB13 in dopamine neurons, braak
- power
- full sample +0.35 (p 0.150, n 18), 95% CI -0.14 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.37 (p 0.132, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.52 (p 0.026, n 18). not the mix.
- skeptic
- leave-one-out range +0.27 to +0.50, sign flips 0; without severely affected donors +0.35 (p 0.150, n 18). fragile.
- cell type
- strongest in microglia: +0.64 (p 0.0042, n 18) vs +0.35 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EFCAB13 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up EFCAB13 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.70 p 0.013 (needs p < 1.4e-4)
Receipts
loading the receipts